HIV / AIDS in the News

Sustaining HIV Impact in MENA: Community Coalitions and Regional Coordination and Leadership - Policy Brief - ReliefWeb

 

Merck, Gilead serve ‘sweet and sour’ spread after HIV win, cancer stumble - BioSpace

 

Staggering Results Show HIV-Transmission Reduced 100% with Twice-Yearly Lenacapavir Injection - Good News Network

 

South Africa launches HIV prevention drug lenacapavir in the country - Shoreline Media Group

 

South Africa launches HIV prevention drug lenacapavir in the country - swiowanewssource.com

 

Wisp Collaborates with Mount Sinai to Expand Access to PrEP and HIV Prevention Across New York State - Business Wire

 

Highly effective prevention drug arrives in South Africa, which has world's highest HIV burden - ABC News - Breaking News, Latest News and Videos

 

Cantor Fitzgerald reiterates Gilead stock rating on HIV trial data - Investing.com

 

Lenacapavir: the HIV Breakthrough Proving Why NIH Funding Matters - Think Global Health

 

Sudan Approves $139 Million Proposal to Combat Malaria, Tuberculosis, and HIV/Aids - allAfrica.com

 

Highly effective prevention drug arrives in South Africa, which has high HIV burden - livingstonenterprise.net

 

Acute Appendicitis at Stem Cell Infusion During Autologous Transplantation for HIV-Associated Diffuse Large B-cell Lymphoma: A Case Report - Cureus

 

June 9 - National HIV Testing Day Events Scheduled for June 27 in Chatham and Glynn Counties - Savannah Business Journal

 

Highly effective prevention drug arrives in South Africa, which has world's highest HIV burden - AP News

 

'We're not seeing a rebound': New data shows HIV services not recovering - Devex

 

Highly effective prevention drug arrives in South Africa, which has world's highest HIV burden - AP News

 

Highly effective prevention drug arrives in South Africa, which has world's highest HIV burden - Oskaloosa Herald

 

Highly effective prevention drug arrives in South Africa, which has world's highest HIV burden - Temple Daily Telegram

 

Gilead-MSD once-weekly oral HIV regimen meets Phase III endpoints - European Pharmaceutical Review

 

HIV services are still falling. A year into the funding crisis, new data shows little recovery. - Clinton Health Access Initiative

 

New Long Acting Oral HIV Regimen Meets Primary Endpoints In Phase 3 Trials - NDTV

 

aidsmap: Worse HIV control at diagnosis doesn’t mean worse lymphoma outcomes - European AIDS Treatment Group

 

Johns Hopkins University: Study explains why HIV sometimes persists in blood post-treatment - European AIDS Treatment Group

 

The Conversation: HIV enters the brain and doesn’t leave – paradoxically, drugs intended to reduce brain inflammation increase virus levels - European AIDS Treatment Group

 

South Africa Rolls Out Game-Changing HIV Shot Amid Funding Shortfalls - nextbillion.net

 

Gilead's lung cancer bid for Trodelvy hits wall, but HIV studies deliver better news - FirstWord Pharma

 

[Press release] Gilead and Merck announce positive topline results from two Phase 3 studies evaluating islatravir/lenacapavir, an oral once-weekly HIV treatment - European AIDS Treatment Group

 

AIDS Memorial Quilt on display as UCSD’s Owen Clinic holds vigil for those lost to HIV - Times of San Diego

 

Defective HIV RNA Linked to Persistent Viremia During Long-Term ART - Genetic Engineering and Biotechnology News

 

A year later, UCSD’s first lung transplant for patient with HIV is called a success - San Diego Union-Tribune